(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2024 (25.01.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/020590 A9

(51) International Patent Classification:
A61P 11/00 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/US2023/070789

(22) International Filing Date:
22 July 2023 (22.07.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/369,152	22 July 2022 (22.07.2022)	US
63/369,158	22 July 2022 (22.07.2022)	US
63/369,165	22 July 2022 (22.07.2022)	US
63/369,175	22 July 2022 (22.07.2022)	US
63/369,202	22 July 2022 (22.07.2022)	US
63/369,203	22 July 2022 (22.07.2022)	US
63/369,204	22 July 2022 (22.07.2022)	US
63/369,206	22 July 2022 (22.07.2022)	US
18/356,891	21 July 2023 (21.07.2023)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 18/356,891 (CIP)
Filed on 21 July 2023 (21.07.2023)

(71) Applicant: **FLAGSHIP PIONEERING INNOVATIONS VI, LLC** [US/US]; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US).

(72) Inventors: **ALIPRANTIS, Antonios, O.**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **COSTELLO, Zachary, Kohl**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **COYLE, Anthony, John**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **HOPSON, Kristen, Park**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **PHENNICIE, Ryan, Terrell**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **RAMOS, Alexis, Hiram**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **ROOT, Adam, Reid**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **DINIC, Lana**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **REIF, Karin, Alma Frieda**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US).

(74) Agent: **MATLOFF, Joshua S.** et al.; Hamilton, Brook, Smith & Reynolds, P.C., 55 Old Bedford Rd., Suite 200, Lincoln, MA 01773 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*
— *with sequence listing part of description (Rule 5.2(a))*
— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(88) Date of publication of the international search report:
29 February 2024 (29.02.2024)

Date of publication of the revised international search report:
30 May 2024 (30.05.2024)

Date of publication of the amended claims:
08 August 2024 (08.08.2024)

(48) Date of publication of this corrected version:
24 October 2024 (24.10.2024)

(15) Information about Correction:
see Notice of 24 October 2024 (24.10.2024)

(54) Title: ANTIGEN BINDING MOLECULES TARGETING THYMIC STROMAL LYMPHOPOIETIN (TSLP)

(57) Abstract: The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating a TSLP-associated disease or condition.

WO 2024/020590 A9

[Continued on next page]

Previous Correction:
see Notice of 30 May 2024 (30.05.2024)